Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2020, with the document issued on March 13, 2020. The filing serves as a report of a foreign private issuer under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is an announcement regarding a supplementary prospectus rather than a financial results report.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing. The primary update is the approval of a supplementary prospectus by the UK Listing Authority.
Guidance, Outlook, and Unusual Items
The filing announces the publication of a supplementary prospectus dated March 13, 2020, for the £20,000,000,000 Euro Medium Term Note Programme involving GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GSK Capital K.K. Copies of the prospectus are available via the National Storage Mechanism (NSM) at www.morningstar.co.uk/uk/NSM. The document includes a disclaimer that the information is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions.
Investor Verification Checklist
- Verify the full text of the supplementary prospectus on the National Storage Mechanism (NSM) website.
- Confirm eligibility to access the information based on the residency restrictions outlined in the base prospectus.
- Review the terms of the £20 billion Euro Medium Term Note Programme for details on issuance conditions.
- Note that this filing contains no operational or financial performance data for the period.